Associated Papers
Case report: A rare case of pyruvate kinase deficiency and Crigler-Najjar syndrome type II with a novel pathogenic variant of PKLR and UGT1A1 mutation.
Wu H et al.
Frontiers in Genetics, 2023
UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2020
A comprehensive assessment of Next-Generation Sequencing variants validation using a secondary technology.
Zheng J et al.
Molecular Genetics & Genomic Medicine, 2019
31165590 (PubMed )
Supplement: MGG3-7-e00748-s004.xlsx › Variants_information
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.
Chen S et al.
The Pharmacogenomics Journal, 2015
The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy.
Laverdière I et al.
Endocrine-related Cancer, 2015
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Lévesque E et al.
The Journal of Pharmacology and Experimental Therapeutics, 2013
Genetic variations and haplotype diversity of the UGT1 gene cluster in the Chinese population.
Yang J et al.
Plos One, 2012
Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population.
Ménard V et al.
Human Mutation, 2009
Select a paper to view details